Natural course of lower urinary tract symptoms following discontinuation of alpha-1-adrenergic blockers in patients with benign prostatic hyperplasia

International Journal of Urology

Volumn 14, Issue 7, 2007, Pages 598-601

  Yokoyama, Teruhiko ^a   Watanabe, Toyohiko ^b   Saika, Takashi ^b   Nasu, Yasutomo ^b   Kumon, Hiromi ^b   Miyaji, Yoshiyuki ^a   Nagai, Atsushi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Alpha adrenergic antagonist; Discontinuation; Prostatic hyperplasia

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; NAFTOPIDIL; TAMSULOSIN; TERAZOSIN; URAPIDIL;

ADULT; AGED; ARTICLE; ASTHENIA; CONTROLLED STUDY; DISEASE COURSE; DIZZINESS; DRUG WITHDRAWAL; EJACULATION DISORDER; FOLLOW UP; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TREATMENT WITHDRAWAL;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATISM;

EID: 34447540332     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01784.x     Document Type: Article

References (19)

1. Arrighi HM, Guess HA, Metter EJ, Fozard JL. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 1990 16 : 253 61.
2. Berry SJ, Coffey DS, Walsch PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J. Urol. 1984 132 : 474 9.
3. Lepor H, Tang R, Shapiro E. The α-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 1993 22 : 301 7.
4. Vallancien G. Alpha-blockers in benign prostatic hyperplasia. Urology 1999 54 : 773 5.
5. Rossi C, Kortmann BB, Sonke GS et al. α-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieved it. J. Urol. 2001 165 : 38 41.
6. De La Rosette LLMCH, Kortmann BBM, Rossi C, Sonke GS, Floratos DL, Kiemeney LALM. Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms. J. Urol. 2002 167 : 1734 9.
7. Verhamme KMC, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph Project. Eur. Urol. 2003 44 : 539 45.
8. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 1999 36 : 1 13.
9. Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H. Use of an α1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J. Urol. 1990 144 : 908 12.
10. Yasuda K, Yamanishi T, Tojo M, Nagashima K, Akimoto S, Shimazaki J. Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. Prostate 1994 25 : 46 52.
11. Lukacs B, Leplege A, Thibault P, Jardin A. Prospective study of men with clinical prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996 48 : 731 40.
12. Roehrborn CG, Oesterling JE, Auerbach S et al. The Hytrin community assessment trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996 47 : 159 68.
13. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Tamuslosin; 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive benign prostatic obstruction: analysis of a European Tamuslosin Study Group. Eur. Urol. 1999 36 : 609 20.
14. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2003 349 : 2387 98.
15. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M. de la Rosette JJ 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH Guidelines). Eur. Urol. 2004 46 : 547 54.
16. Debruyne FMJ. BPH symptoms do not return to baseline after withdrawal of terazosin. J. Urol. Suppl. 1997 157 : 252, (Abstract 986).
17. Kaplan SA, Reis RB, Cologna A et al. Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms. Urology 1998 52 : 12 16.
18. Yanardag H, Goktas S, Kibar Y, Kilic S, Erduran D. Intermittent tamuslosin therapy in men with lower urinary tract symptoms. J. Urol. 2005 173 : 155 67.
19. Kobayashi M, Tokue A, Morita T. Discontinuation of tamsulosin treatment in men with lower urinary tract symptoms: a pilot study. Urol. Int. 2006 76 : 304 8.